此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

吸收吸收以增强毒性消除药物 (MATRIX)

2026年9月18日 更新者:Universitair Ziekenhuis Brussel

In this trial the investigators assess the effectiveness of applying a hemadsorber (cytosorb®) in removing benzodiazepines or tricyclic antidepressants in intoxicated patients admitted to ICU with prolonged impaired consciousness. This is a one arm interventional investigation where a hemadsorption filter is applied in patients fulfilling inclusion criteria 8 hours after admission. Plasma titer of the neurodepressing drug will be collected sequentially both before and after start of hemadsorption to evaluate the speed of drug elimination before and after application of a hemadsorption filter. Pre- and post filter titers will be obtained to evaluate adsorbability and to evaluate time to saturation of the filter.

研究概览

地位

招聘中

条件

详细说明

In this prospective interventional study with medical device, the investigotors would include 18 patients admitted to ICU after an intoxication with a quantifiable neurodepressing drugs (type benzodiazepines or tricyclic antidepressants) and with impaired consciousness defined as need for intubation or need for Flumazenil to prevent intubation. Naloxone is administered per standard of care to identify if opioid intoxications is the main reason of neurodepression. Patients requiring mechanical ventilation for other reasons than impaired consciousness due to this intoxication or indication for prolonged use of sedatives are excluded.

Patients with at least one risk factor for delayed drug elimination (Chronic kidney disease G3b or CHILD-Pugh B or C) and persisting impaired consciousness after eight hours (including patients with persisting need for flumazenil) and having 5 plasma titers of the neurodepressing drug with intervals of 2 hours will be initiated on a hemadsorption filter after contact between the treating team and either dr. Michaël Mekeirele or dr. Tim Balthazar to verify inclusion criteria. Patients fulfilling inclusion criteria but lacking the 5 plasma titers will get additional plasma titers with intervals of 2 hours until 5 plasma titers are obtained. If these patients still fulfill inclusion criteria at that time then a hemadosorption filter will be initiated.

After starting hemadsorption a plasma titer pre- and post filter will be obtained after 15 minutes and every 4 hours after starting hemadsorption for the first 24 hours. After this timepoint additional plasma titers will be obtained every 24 hours until stopping hemadsorption or normalisation of the plasma titer.

研究类型

介入性

注册 (估计的)

18

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Brussels Capital
      • Brussels、Brussels Capital、比利时、1090
        • 招聘中
        • Universitair Ziekenhuis Brussel
        • 接触:
        • 接触:
        • 首席研究员:
          • Michaël Mekeirele, Medical Doctor

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. older than18 years
  2. Admission to ICU
  3. GCS < 8 or requiring Flumazenil 8 hours after hospital admission
  4. Having an intoxication with a benzodiazepine or tricyclic antidepressant that we can measure/quantify
  5. Having a risk factor for delayed drug elimination defined as either Cirrhosis CHILD B/C or chronic kidney insufficiency KDIGO 3b or worse

Exclusion Criteria:

  1. Pregnant patient
  2. Patients in chronic dialysis before admission
  3. Need for mechanical ventilation for other reasons than intoxications (e.g. pneumonia, neurotrauma)
  4. Concomitant pathology requiring continued intravenous sedation
  5. Known history of seizures
  6. Contra-indication to heparin use
  7. DNR restricting the use of mechanical ventilation or dialysis

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Hemadsorption

Hemadsorption via a dialysis catheter will be performed in patients who are unconscious due to an intoxication with quantifiable benzodiazepines or tricyclic antidepressants 8 hours after admission. Before and after application fo this hemadsorption filter plasma titers of this drug will be obtained. After application of the hemadsorption filter pre- and post-filter titers will be obtained.

Plasma titers neurodepressing drug:

  • At admission to the hospital (standard of care)
  • 2 hours after admission (+/- 15 minutes)
  • 4 hours after admission (+/- 15 minutes)
  • 6 hours after admission (+/- 15 minutes)
  • 8 hours after admission (+/- 15 minutes)
  • Just before start hemadsorption

Hemadsorption via dialysis catheter in patients still fulfilling inclusion criteria 8 hours after admission.

Subsequent plasma titers pre- and post-hemadosorption filter:

  • 15 minutes after start of hemadsorption (+ 15 minutes)
  • 4 hours after start of hemadsorption (+/- 15 minutes)
  • 8 hours after start of hemadsorption (+/- 15 minutes)
  • 12 hours after start of hemadsorption (+/- 15 minutes)
  • 16 hours after start of hemadsorption (+/- 15 minutes)
  • 20 hours after start of hemadsorption (+/- 15 minutes)
  • 24 hours after start of hemadsorption (+/- 15 minutes)
  • Every other 24 hours until cessation of hemadsorption or normalization of the plasma titer (+/- 15 minutes)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Difference in time to upper limit of normal of the dosed drug with versus without hemadsorption
大体时间:From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Based on plasma titers before start of hemadsorption the half life of the drug can be calculated. A theoretical intersection with the upper boundary of normal of the intoxicated drug plasma titer can be calculated. This will be statistically compared to the real time of attaining this titer after start of hemadsorption.

From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

次要结果测量

结果测量
措施说明
大体时间
Adsorbability of the individual neurodepressing drugs
大体时间:From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Comparing the pre- and post filter titer of the neurodepressing drug the adsorbability can be observed.

From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days
Time to saturation of hemadsorption filter
大体时间:From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Comparing the pre- and post filter titer of the neurodepressing drug the time to saturation can be observed

From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days
Catheter related complications
大体时间:From enrollment to the removal of the dialysis catheter +/- 3 days

Catheter related complications (eg bleeding, infection) will be noted

From enrollment to the removal of the dialysis catheter +/- 3 days
Seizures during hemadsorption therapy
大体时间:From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Seizures during hemadsorption therapy will be noted

From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days
Bleeding during hemadsorption therapy
大体时间:From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Bleeding during hemadsorption therapy will be noted

From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days
Cost effectiveness of applying a Cytosorb® hemadsorption filter
大体时间:From enrollment to discharge from ICU (+/- 1 week)

Duration of ICU stay, duration of ventilation, cost of a hemadsorption filter and disposables amongst others will be used for an evaluation of cost effectiveness

From enrollment to discharge from ICU (+/- 1 week)
Duration mechanical ventilation
大体时间:From enrollment to extubation (+/- 3 days)

Time to extubation and stop of flumazenil will be noted

From enrollment to extubation (+/- 3 days)
Duration ICU stay
大体时间:From enrollment to discharge from ICU (+/- 1 week)

Time to discharge will be noted

From enrollment to discharge from ICU (+/- 1 week)
Need and duration vasopressors
大体时间:From enrollment to stop of vasopressors (+/- 3 days)

Time untill discontinuation of vasopressors will be noted

From enrollment to stop of vasopressors (+/- 3 days)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Michaël Mekeirele, Medical Doctor、Universitair Ziekenhuis Brussel

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月1日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2029年1月1日

研究注册日期

首次提交

2025年4月2日

首先提交符合 QC 标准的

2025年4月3日

首次发布 (实际的)

2025年4月10日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月18日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • CIV-24-12-050174

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Single center study

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅